Entinostat (MS-275)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

294 publications

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 57 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Entinostat (MS-275) has been cited by 294 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwME[xJO69VQ>? NWC2fWJYW0GQR1XS
ALL-PO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG1fFJWUUN3ME2wMlA3OzV3IN88US=> NHTae49USU6JRWK=
697 NFjKeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[4S2hKSzVyPUCuNFk6PzZizszN Mli1V2FPT0WU
NCI-H748 NI\DUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXBOXBjUUN3ME2wMlExOzN2IN88US=> NEfCeFVUSU6JRWK=
NKM-1 NHr3V3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Pu[2lEPTB;MD6xNFkyOiEQvF2= M3f2dXNCVkeHUh?=
ES1 M2HNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\ifWlEPTB;MD6xNVI2PSEQvF2= MkiwV2FPT0WU
NCI-H1963 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1VYJxUUN3ME2wMlEyPTd7IN88US=> NUTJbXJxW0GQR1XS
NCI-H1417 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjOXZNKSzVyPUCuNVI6PzRizszN MWLTRW5ITVJ?
NEC8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;nTmlEPTB;MD6xN|UzPyEQvF2= M1XsdHNCVkeHUh?=
CRO-AP2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLmTWM2OD1yLkG2PFg6KM7:TR?= MlfYV2FPT0WU
A3-KAW NGK2cnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP0Z3hjUUN3ME2wMlE4PjJ5IN88US=> M2DQ[HNCVkeHUh?=
SF539 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\aUWlEPTB;MD6xPVU6OyEQvF2= NFnvUWhUSU6JRWK=
NOS-1 NX7RPHVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnXbodVUUN3ME2wMlE6PjF7IN88US=> MkflV2FPT0WU
NTERA-S-cl-D1 NXz5NlBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nZVmlEPTB;MD6yNFEyOyEQvF2= NWHITmxCW0GQR1XS
COR-L88 NEnHeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTwcItMUUN3ME2wMlIzQTV7IN88US=> NEDjPZlUSU6JRWK=
EM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rSd2lEPTB;MD6yOFA4QSEQvF2= M4fJcXNCVkeHUh?=
KARPAS-45 NIfkPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfvWpExUUN3ME2wMlI4QDN|IN88US=> MU\TRW5ITVJ?
DSH1 NXv4ZVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTvenN[UUN3ME2wMlI5PzB6IN88US=> NGPOW25USU6JRWK=
HT-144 M4HaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrabo1KSzVyPUCuN|AzPTZizszN NYHUUYRSW0GQR1XS
ATN-1 NEnUfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;1d2lEPTB;MD6zNFU4PiEQvF2= MoDoV2FPT0WU
HEL NH:wZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTtT|FUUUN3ME2wMlMyOzR6IN88US=> MoqzV2FPT0WU
NB12 MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwM{G3OVYh|ryP NUK3T4VJW0GQR1XS
LU-139 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLzTWM2OD1yLkOzOVEh|ryP NH\SemdUSU6JRWK=
J-RT3-T3-5 M4HTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwM{O3NVYh|ryP NIr4RmlUSU6JRWK=
MOLT-13 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2O2lEPTB;MD6zN|gyKM7:TR?= Mn7GV2FPT0WU
SR M1[3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zZc2lEPTB;MD6zOFI3OSEQvF2= MYXTRW5ITVJ?
CMK NYLRd2JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwM{W3Nlch|ryP M1TPZXNCVkeHUh?=
ES8 M3HjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmewTWM2OD1yLkO2NFIzKM7:TR?= M4LJb3NCVkeHUh?=
LB647-SCLC M1zWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK3TJdtUUN3ME2wMlM3PzNizszN MYrTRW5ITVJ?
TE-8 M2rCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHKeYlKSzVyPUCuN|Y6OzVizszN NFu1TmVUSU6JRWK=
BV-173 NGL4OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7CTZNKSzVyPUCuN|cyOjFizszN MW\TRW5ITVJ?
DEL M{SxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwM{e0PFch|ryP M1TYeXNCVkeHUh?=
ARH-77 M3TDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHpdlBKSzVyPUCuN|gyQTNizszN NHzv[lBUSU6JRWK=
NCCIT M2fBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLKWpptUUN3ME2wMlM5PjR7IN88US=> MWfTRW5ITVJ?
RPMI-8402 M4PxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37tc2lEPTB;MD6zPFcxOSEQvF2= NGfXWnJUSU6JRWK=
MONO-MAC-6 NFXDb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{i3O|Yh|ryP MmW3V2FPT0WU
SK-MM-2 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwM{m4Olgh|ryP NIe5[pZUSU6JRWK=
CHP-126 NFn2PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTSTWM2OD1yLkSwNlMyKM7:TR?= MkPPV2FPT0WU
A101D MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNECzJO69VQ>? MkXpV2FPT0WU
SCH NYHqU4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO1RpNkUUN3ME2wMlQxOzR{IN88US=> NGfPV|BUSU6JRWK=
NMC-G1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K1UmlEPTB;MD60NFM3PyEQvF2= NXfBfVlZW0GQR1XS
NCI-H209 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\RTWM2OD1yLkSwOlE{KM7:TR?= NYnlS3JnW0GQR1XS
MOLT-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHuTWM2OD1yLkSxNFE4KM7:TR?= NGfMflRUSU6JRWK=
RPMI-6666 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTXTWM2OD1yLkSxNVIh|ryP MU\TRW5ITVJ?
OPM-2 NEm2[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNEG1NVMh|ryP M4jpenNCVkeHUh?=
MRK-nu-1 M1rhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELEOXFKSzVyPUCuOFMyPTNizszN MVvTRW5ITVJ?
BC-1 NXXnPWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXCTWM2OD1yLkSzOFA{KM7:TR?= M4HETXNCVkeHUh?=
MHH-NB-11 NVfscYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj4TWM2OD1yLkSzOFU{KM7:TR?= M1\vUXNCVkeHUh?=
Ramos-2G6-4C10 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TyW2lEPTB;MD60N|g6PyEQvF2= NUT1eZNkW0GQR1XS
LS-513 NVLJSGlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPPdo93UUN3ME2wMlQ1PTBzIN88US=> MmTvV2FPT0WU
K5 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZZYNKSzVyPUCuOFcxOjVizszN MVjTRW5ITVJ?
HOP-62 NYLITIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNEizOVgh|ryP Ml[yV2FPT0WU
NCI-H187 NGrFcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\NPFlIUUN3ME2wMlQ6OjJ5IN88US=> MYnTRW5ITVJ?
BE-13 NGTFenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO2R4xuUUN3ME2wMlQ6PjZzIN88US=> NEPpO|lUSU6JRWK=
HC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7XNmxEUUN3ME2wMlUxPDd|IN88US=> MUXTRW5ITVJ?
ACN MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNUGwNlgh|ryP MknaV2FPT0WU
HCC1599 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\UWWlEPTB;MD61NVU4KM7:TR?= M{nobXNCVkeHUh?=
MV-4-11 NGfHUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHsTWM2OD1yLkWzNFQyKM7:TR?= NVPH[otqW0GQR1XS
LC-2-ad Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MormTWM2OD1yLkWzOlY{KM7:TR?= M3PiS3NCVkeHUh?=
HL-60 NITnNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr6bolKSzVyPUCuOVQzPjFizszN M17vZ3NCVkeHUh?=
NB17 M2rOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQTWM2OD1yLkW0N|gh|ryP MYnTRW5ITVJ?
TE-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1yLkW1N|A3KM7:TR?= NYrCbYxKW0GQR1XS
NCI-H524 NXK3WWozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G0SmlEPTB;MD61OVQxOSEQvF2= M{P6OnNCVkeHUh?=
MZ7-mel Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjOZVNKSzVyPUCuOVYyODVizszN NHXzOYFUSU6JRWK=
L-363 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLad5NKSzVyPUCuOVY3PTdizszN NEn4N4JUSU6JRWK=
BL-41 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;lb3RKSzVyPUCuOVY5QDlizszN MWrTRW5ITVJ?
LU-134-A MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D5XmlEPTB;MD61O|A4OyEQvF2= MX3TRW5ITVJ?
SIG-M5 NUn1VJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCyUo9uUUN3ME2wMlU4QDR6IN88US=> M1y3NXNCVkeHUh?=
ONS-76 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDuWpliUUN3ME2wMlU5OjR{IN88US=> MW\TRW5ITVJ?
KARPAS-299 NEDaWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX5TWM2OD1yLkW4OVA1KM7:TR?= NELjOZFUSU6JRWK=
DU-4475 NX3FT|JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrZco04UUN3ME2wMlU5PzB|IN88US=> M{DMTXNCVkeHUh?=
NB69 Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q5R2lEPTB;MD61PVgzPSEQvF2= M4\CTHNCVkeHUh?=
MHH-PREB-1 NH3RbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNkC3NVkh|ryP M3;H[3NCVkeHUh?=
LU-165 M1fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq0PYtKSzVyPUCuOlE5OTJizszN MluzV2FPT0WU
LOUCY M{K4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe4TpBKSzVyPUCuOlM{PjRizszN Mo\TV2FPT0WU
NCI-H526 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwNkO1OFEh|ryP NV73OHZnW0GQR1XS
KE-37 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TL[mlEPTB;MD62OFI4PiEQvF2= NVXIXlY1W0GQR1XS
NALM-6 M1H6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1niZ2lEPTB;MD62OFg3KM7:TR?= MXHTRW5ITVJ?
CW-2 NVrZVIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\CZmlEPTB;MD62OVc6PCEQvF2= MorJV2FPT0WU
SU-DHL-1 NHf2RppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DCfmlEPTB;MD62OVk1PyEQvF2= NUnmVFhjW0GQR1XS
NB13 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[yTWM2OD1yLk[2PFE4KM7:TR?= NXrUblA{W0GQR1XS
QIMR-WIL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm4dIVKSzVyPUCuOlg{PDNizszN M3\QZnNCVkeHUh?=
ECC12 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH5ToxrUUN3ME2wMlcxODh4IN88US=> NEKxelJUSU6JRWK=
KALS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi1VYZKUUN3ME2wMlcxPDl{IN88US=> Ml7uV2FPT0WU
COR-L279 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ZcWhKSzVyPUCuO|A6QTZizszN Ml24V2FPT0WU
NB14 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwN{K2NVch|ryP MkjlV2FPT0WU
CCRF-CEM M37y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwN{S2OlEh|ryP MVfTRW5ITVJ?
SW954 M4e5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xkc2lEPTB;MD63OVk6QSEQvF2= NHXMRodUSU6JRWK=
IST-SL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\ZeWFKSzVyPUCuO|c{PDhizszN NYW1OIIxW0GQR1XS
LAMA-84 NVjjRZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwN{e1Olch|ryP NGqzeHZUSU6JRWK=
Daudi NWmwZ3VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfqXmt3UUN3ME2wMlc4PjhzIN88US=> NUnIVFlbW0GQR1XS
BC-3 NHz0[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHxfWVYUUN3ME2wMlc5OzB6IN88US=> NGfEdVRUSU6JRWK=
HCC2998 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwN{izOkDPxE1? NFftOmdUSU6JRWK=
NCI-H69 NFrtW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PyUmlEPTB;MD64NFE1PyEQvF2= MkDNV2FPT0WU
CPC-N Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwOEC1NlQh|ryP MkSxV2FPT0WU
NOMO-1 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH5cppKSzVyPUCuPFExQDRizszN MY\TRW5ITVJ?
CESS NX;FSZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOwVpliUUN3ME2wMlgyOTl5IN88US=> NIG3WJZUSU6JRWK=
LC4-1 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:2[WlEPTB;MD64OFAxPyEQvF2= NGW0fnpUSU6JRWK=
BL-70 NHLIVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPBTWM2OD1yLki1O|AzKM7:TR?= MlzDV2FPT0WU
ES4 NXPiR5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nq[2lEPTB;MD64OVg3QCEQvF2= NXvYTnJlW0GQR1XS
HCE-T NV24O|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTYTWM2OD1yLki3NVcyKM7:TR?= NHLiUGJUSU6JRWK=
JAR MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDaS3NKSzVyPUCuPFc5OjdizszN NI\1VoZUSU6JRWK=
ST486 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwOEe5NVch|ryP NHfK[llUSU6JRWK=
KS-1 NEjiVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W5fmlEPTB;MD64PFA6PiEQvF2= MlvWV2FPT0WU
GDM-1 NVP4UWFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwOEi2PFch|ryP M1PF[nNCVkeHUh?=
EHEB NV7l[44xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\zfHhZUUN3ME2wMlkzPTh3IN88US=> NVPwN4Z5W0GQR1XS
LB2518-MEL M1[zNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwOUOyPFQh|ryP MmfMV2FPT0WU
GOTO M4P0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDsT2dKSzVyPUCuPVUxPzZizszN M2GwZnNCVkeHUh?=
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjmUIFxUUN3ME2wMlk2QTBzIN88US=> NIDmUopUSU6JRWK=
ES6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xUVNKSzVyPUCuPVY1OzdizszN M1;mV3NCVkeHUh?=
OS-RC-2 NUeyO3dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwOU[4N{DPxE1? Ml7zV2FPT0WU
DMS-153 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwOUe0Olkh|ryP M{DNTXNCVkeHUh?=
SK-PN-DW M3TPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwOUe4N|Eh|ryP NVyxfG56W0GQR1XS
HH NV\UO2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[zTWM2OD1yLkm4PVU6KM7:TR?= NHr6Z5RUSU6JRWK=
SH-4 NXPycmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPpcVdrUUN3ME2xMlAzPDFizszN Moe2V2FPT0WU
MOLT-4 M{HmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMEO0OVQh|ryP Mmm2V2FPT0WU
TGW M1\MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M124TGlEPTB;MT6wO|Y4PSEQvF2= MYDTRW5ITVJ?
L-540 M{HSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLpNmlKSzVyPUGuNVA3ODRizszN MnPPV2FPT0WU
PF-382 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fmXmlEPTB;MT6xNVUyOyEQvF2= MX3TRW5ITVJ?
LC-1F NF7abGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWyPGhKSzVyPUGuNVIxODdizszN Mn\qV2FPT0WU
OVCAR-4 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nqPGlEPTB;MT6xN|E3PSEQvF2= Mn;BV2FPT0WU
A4-Fuk M2KybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK2b4p4UUN3ME2xMlE2OzZ2IN88US=> M3rlOHNCVkeHUh?=
HCC2218 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S0Z2lEPTB;MT6xOlY1OSEQvF2= NVfRO5hMW0GQR1XS
HAL-01 NVLZNHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMU[5OFMh|ryP NHfMS2lUSU6JRWK=
IST-MEL1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPNXphKSzVyPUGuNVc3PTlizszN MVrTRW5ITVJ?
NCI-H719 NI\oRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwMUe4PVgh|ryP NXHHXVVvW0GQR1XS
EVSA-T NXHqWGR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwMUixNVQh|ryP M2HZRXNCVkeHUh?=
SK-NEP-1 NInsVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rUWGlEPTB;MT6yNFI3PiEQvF2= NFz3TFhUSU6JRWK=
OCUB-M M1PyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TSS2lEPTB;MT6yNVQ5QSEQvF2= NIC2[GZUSU6JRWK=
MEG-01 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoixTWM2OD1zLkKyNVE5KM7:TR?= M2HuUnNCVkeHUh?=
no-10 NWDMb2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[yTWM2OD1zLkKzNVEzKM7:TR?= MmCzV2FPT0WU
MHH-CALL-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vnU2lEPTB;MT6yOFczOSEQvF2= NH34VWVUSU6JRWK=
SK-N-DZ NGm4RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHpR41KSzVyPUGuNlQ4PzZizszN NYH0RpBKW0GQR1XS
SCLC-21H M2r6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TUSmlEPTB;MT6yOlQ4QCEQvF2= NWLVUVVjW0GQR1XS
CTV-1 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITTfGhKSzVyPUGuNlc1OjVizszN MmHTV2FPT0WU
NB1 NFrMdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjEenM5UUN3ME2xMlI4PzN{IN88US=> NFzoPWpUSU6JRWK=
NCI-H64 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMki0OlIh|ryP MUHTRW5ITVJ?
MDA-MB-134-VI MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvSUndIUUN3ME2xMlI5PTd5IN88US=> NEfoe3JUSU6JRWK=
LB2241-RCC M17vb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHlTWM2OD1zLkK4OlY{KM7:TR?= MY\TRW5ITVJ?
8-MG-BA MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMki4OlYh|ryP NEHFSpFUSU6JRWK=
LP-1 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnIUHRKSzVyPUGuNlk6PDdizszN NEXrWHZUSU6JRWK=
LS-411N NUOzcodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrJVolKSzVyPUGuN|A6QThizszN MlHBV2FPT0WU
CAL-148 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwM{K1OFIh|ryP NVfjeHp3W0GQR1XS
NCI-H2171 NX3INJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q3dGlEPTB;MT6zOFUxOiEQvF2= MW\TRW5ITVJ?
JiyoyeP-2003 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXQTWM2OD1zLkO1N|kh|ryP NYf4emdVW0GQR1XS
NCI-H2107 NFmyPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwM{W4PFMh|ryP MmDvV2FPT0WU
BB30-HNC MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G2SmlEPTB;MT6zPFk4QCEQvF2= MVTTRW5ITVJ?
K-562 NH;pbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LNOWlEPTB;MT6zPVIyQSEQvF2= NEi4XI5USU6JRWK=
PSN1 M4DQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP4TWM2OD1zLkSyNlg4KM7:TR?= MknWV2FPT0WU
HCC2157 M{LVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XmNWlEPTB;MT60NlY6OSEQvF2= MXjTRW5ITVJ?
SBC-1 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHZTWM2OD1zLkSyO|QyKM7:TR?= MnTOV2FPT0WU
MC116 NGjEblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwNEO2NVUh|ryP MVXTRW5ITVJ?
KARPAS-422 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;xTWM2OD1zLkS1N|U5KM7:TR?= MoTGV2FPT0WU
LB996-RCC NV:4ZlBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3DZmxKSzVyPUGuOFcyODNizszN NGq1TpBUSU6JRWK=
MSTO-211H NWS5XVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv5T3JKSzVyPUGuOFc6QDdizszN NUjDeIdFW0GQR1XS
BT-474 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwNUG3OlQh|ryP M2fkNnNCVkeHUh?=
A388 NX7LWXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjGRY1KSzVyPUGuOVE6PDVizszN NYn2Om9wW0GQR1XS
SJSA-1 NEn3dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwNUKyOkDPxE1? MXzTRW5ITVJ?
COLO-829 M3XmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwNlFKSzVyPUGuOVM2PjRizszN NVTTdGhKW0GQR1XS
KM-H2 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD1VY5PUUN3ME2xMlU3PjdizszN MkPWV2FPT0WU
GR-ST MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwNU[4NkDPxE1? MWjTRW5ITVJ?
RPMI-8866 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITUSJpKSzVyPUGuOlAyPDRizszN MoqwV2FPT0WU
KG-1 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTMTWM2OD1zLk[xPVAyKM7:TR?= NX3SOIZTW0GQR1XS
NCI-H82 NXLLboJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSwTWM2OD1zLk[zOFA3KM7:TR?= M3vqfnNCVkeHUh?=
LB1047-RCC MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\IV3FKSzVyPUGuOlM1PTlizszN NIrW[3FUSU6JRWK=
KM12 M3\2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHxTYZZUUN3ME2xMlY1PyEQvF2= MYrTRW5ITVJ?
NB5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXRTWM2OD1zLk[1Olc4KM7:TR?= MlXKV2FPT0WU
HDLM-2 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;GTWM2OD1zLk[4NlgyKM7:TR?= M3fTUXNCVkeHUh?=
KU812 NFrXbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfNSI1KSzVyPUGuOlk3ODVizszN NETQ[YFUSU6JRWK=
DB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwN{CzOVMh|ryP NEjXTWtUSU6JRWK=
HD-MY-Z M3GwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHCTWM2OD1zLke1NlM1KM7:TR?= NWjyfm1rW0GQR1XS
KURAMOCHI M3zoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzMTWM2OD1zLke3NlA4KM7:TR?= MUnTRW5ITVJ?
ETK-1 NWTG[mIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTTTWM2OD1zLke4PFc6KM7:TR?= NYjkflVWW0GQR1XS
SK-UT-1 NWn5S|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwN{mzPFgh|ryP Ml[xV2FPT0WU
HUTU-80 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT6TWM2OD1zLke5OVA5KM7:TR?= M2nOUXNCVkeHUh?=
ES7 M{PD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH1eG1SUUN3ME2xMlgxOzB{IN88US=> NEHF[olUSU6JRWK=
SW872 M1rDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq2V29KSzVyPUGuPFE{QTVizszN NHjaNVFUSU6JRWK=
TK10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfhTWM2OD1zLkizNVA5KM7:TR?= M4nU[3NCVkeHUh?=
LB831-BLC M3Xvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\QZmRKSzVyPUGuPFM2PjNizszN M{Xue3NCVkeHUh?=
TE-9 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SzcGlEPTB;MT64OFQzOiEQvF2= MV\TRW5ITVJ?
MLMA MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfhTWM2OD1zLki4NlM1KM7:TR?= M2D4XHNCVkeHUh?=
D-542MG MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq1TWM2OD1zLki5N|c{KM7:TR?= NEfPcFVUSU6JRWK=
EW-16 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HOUWlEPTB;MT65NlczKM7:TR?= MmDlV2FPT0WU
LOXIMVI MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7TTWM2OD1zLkmzNlgh|ryP M3fBXnNCVkeHUh?=
GB-1 NHzJc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;6b3VKSzVyPUGuPVM5PjZizszN MoLxV2FPT0WU
IST-SL2 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq1eoR4UUN3ME2yMlAxOjZ{IN88US=> NH3nR29USU6JRWK=
LAN-6 M4PJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJwMEG5OlYh|ryP NEfZ[mJUSU6JRWK=
NCI-H510A MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTCR4l1UUN3ME2yMlA1PTB{IN88US=> NH7y[|RUSU6JRWK=
NCI-H1092 M3n4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fX[WlEPTB;Mj6wOVEzPCEQvF2= MkHrV2FPT0WU
HT M33kdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwMUC0OVQh|ryP NX\ESIhJW0GQR1XS
RL95-2 NG\ifXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vJ[2lEPTB;Mj6xNVQ5OiEQvF2= MYfTRW5ITVJ?
NCI-H1355 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTKdG1{UUN3ME2yMlEyPzl{IN88US=> M{fJ[HNCVkeHUh?=
NCI-H720 M4ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLzTWM2OD1{LkG2PFc{KM7:TR?= NXy3VHRzW0GQR1XS
NCI-H1522 NHnqfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7LVYN6UUN3ME2yMlIyPzJ|IN88US=> M1LnbnNCVkeHUh?=
LB373-MEL-D NHuz[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfuVIRKSzVyPUKuNlY6ODJizszN NHzNdmhUSU6JRWK=
DG-75 NIDzeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LkOmlEPTB;Mj6yO|E1QCEQvF2= MVHTRW5ITVJ?
ML-2 NGLWRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvsWWNZUUN3ME2yMlMzQDV3IN88US=> MmntV2FPT0WU
SF126 M{LrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLKOHZjUUN3ME2yMlM{ODl2IN88US=> MnzaV2FPT0WU
MPP-89 NWfO[|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTVTWM2OD1{LkOzNVQ2KM7:TR?= M3TrPXNCVkeHUh?=
NCI-H345 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPKTWM2OD1{LkOzNlc4KM7:TR?= NXi2cnVOW0GQR1XS
LS-123 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HofWlEPTB;Mj6zOFk{PiEQvF2= MmL1V2FPT0WU
NB10 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNEGwPVIh|ryP NWrCclRxW0GQR1XS
CGTH-W-1 NYPEW3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:5TWM2OD1{LkSyNlY4KM7:TR?= NUXkTHE5W0GQR1XS
CP66-MEL NXjlSmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5dmlEPTB;Mj60O|c4KM7:TR?= NEjTU|dUSU6JRWK=
L-428 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLZTWM2OD1{LkS4OVIyKM7:TR?= M2flRXNCVkeHUh?=
DMS-79 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwNUSxNFMh|ryP MWTTRW5ITVJ?
NCI-H1882 NGjXdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorCTWM2OD1{Lk[3OVYzKM7:TR?= MorJV2FPT0WU
KGN NHroSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf6SZJKSzVyPUKuO|Y5PzZizszN M{fYfnNCVkeHUh?=
EW-1 NVXteYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwN{ewPFMh|ryP MmfSV2FPT0WU
U-266 M1XsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLLb5JKSzVyPUKuPFQ5OjNizszN NF3PPZJUSU6JRWK=
COLO-320-HSR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LJd2lEPTB;Mj64OVY1OSEQvF2= MlTjV2FPT0WU
KMOE-2 M4P4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJwOEe3NVEh|ryP MVvTRW5ITVJ?
BB49-HNC MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXr[ZVlUUN3ME2yMlkzPDhizszN NUPKSYw4W0GQR1XS
GI-1 NEfaN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[2PINUUUN3ME2yMlkzQTV5IN88US=> MVLTRW5ITVJ?
NCI-H1304 M{T3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\2TWM2OD1|LkCwOVEyKM7:TR?= M{DoV3NCVkeHUh?=
NCI-H2227 NXnGPWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPFTWM2OD1|LkCyNFc6KM7:TR?= NF32RWRUSU6JRWK=
U-87-MG M2m4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwMEO1NVMh|ryP M4LEbHNCVkeHUh?=
NCI-H747 NEW0XoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPVTWM2OD1|LkC1NlA3KM7:TR?= Mm\NV2FPT0WU
CTB-1 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjqTWM2OD1|LkC1N|c3KM7:TR?= MlvTV2FPT0WU
RPMI-8226 NESyUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjFfWFoUUN3ME2zMlE1Ozd6IN88US=> Mnn3V2FPT0WU
NCI-H2141 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTNwMU[1OlYh|ryP M{TvR3NCVkeHUh?=
IST-MES1 NHnkWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwMUiyO|kh|ryP M1;B[nNCVkeHUh?=
TE-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvXcHZwUUN3ME2zMlIyOzR{IN88US=> NHrMemdUSU6JRWK=
UACC-257 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLsW2RRUUN3ME2zMlQ{PjV7IN88US=> MWDTRW5ITVJ?
SK-N-FI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNwNEWyNlch|ryP MWTTRW5ITVJ?
MFH-ino MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXMTWM2OD1|LkS2OVg6KM7:TR?= NUDZUYRuW0GQR1XS
SF268 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXDTWM2OD1|LkS4NVc1KM7:TR?= NXjmcldqW0GQR1XS
TE-12 NGnLdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XM[GlEPTB;Mz61NVY6QSEQvF2= MnvSV2FPT0WU
NB6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLHfWM6UUN3ME2zMlU2PTZ|IN88US=> Mkn2V2FPT0WU
DJM-1 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHJTWM2OD1|LkW5PFk6KM7:TR?= NYr4[Y1OW0GQR1XS
MZ1-PC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTNwNkG2NlQh|ryP M3fCRXNCVkeHUh?=
OCI-AML2 NXHHSZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLaTmhKSzVyPUOuOlI3PzFizszN MXjTRW5ITVJ?
NCI-H1155 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfzTWM2OD1|LkewPVQ4KM7:TR?= MUPTRW5ITVJ?
RKO NYXDeFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULneGxTUUN3ME2zMlc4OTh7IN88US=> NXXNVnRDW0GQR1XS
ECC4 NI\ZeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwOUexPVUh|ryP M3L1O3NCVkeHUh?=
BB65-RCC NXfBcFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXhXmtKSzVyPUOuPVc2PDdizszN M{TvR3NCVkeHUh?=
EB-3 NFXtVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3lUVFsUUN3ME2zMlk6PjN|IN88US=> M4mwd3NCVkeHUh?=
SHP-77 NHHhUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTRwMEC1NlQh|ryP NUfob|lQW0GQR1XS
NCI-H2196 NELEW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXXcYFKSzVyPUSuNFU3OjVizszN MXPTRW5ITVJ?
GI-ME-N NFfZO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTXTWM2OD12LkC2N|k6KM7:TR?= NXyxNGFbW0GQR1XS
MN-60 NE\PXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PwZmlEPTB;ND6xNFg4KM7:TR?= MX3TRW5ITVJ?
NCI-H1694 M1:5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPJVXlKSzVyPUSuNVM1ODVizszN Ml3wV2FPT0WU
LU-65 M4fXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjvOnRKSzVyPUSuNVU{OzJizszN M3[zbXNCVkeHUh?=
NCI-H1436 NFrqWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3uTWM2OD12LkG4N|M{KM7:TR?= M2nwSHNCVkeHUh?=
KINGS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7hfHZnUUN3ME20MlMyPDN{IN88US=> MlTsV2FPT0WU
GT3TKB NGS4SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPJU4FnUUN3ME20MlM{OjZ6IN88US=> MVTTRW5ITVJ?
Becker MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXsOJRKSzVyPUSuN|c{OTJizszN NIjhXIxUSU6JRWK=
HCC1187 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjNe2lKSzVyPUSuPFk3PTdizszN MXHTRW5ITVJ?
D-502MG M3m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DRVGlEPTB;NT6wNFQyPiEQvF2= M2HlPHNCVkeHUh?=
VA-ES-BJ MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LCVGlEPTB;NT6xN|c4QCEQvF2= NVn5fZdpW0GQR1XS
NB7 NEHDOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK4TlRKSzVyPUWuNVQyOTJizszN MmGxV2FPT0WU
SW962 NV3IXGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTVwM{i4NVQh|ryP NX65NnUzW0GQR1XS
no-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVezPHpIUUN3ME21Mlc3OzR|IN88US=> NXjpTnExW0GQR1XS
KNS-81-FD NUe4TJllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTVwOUC2PVQh|ryP NILzb3dUSU6JRWK=
COLO-684 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zQ[GlEPTB;NT65PVQ6PCEQvF2= NFTPPXRUSU6JRWK=
D-263MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTZwMEi4PVUh|ryP NGfYXZVUSU6JRWK=
EW-24 NGDYUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX33enFUUUN3ME22MlI5PTFizszN NYTQfZFSW0GQR1XS
TE-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDWcXJKSzVyPU[uOFI3OjNizszN MXjTRW5ITVJ?
EKVX M{\XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\pOWlEPTB;Nj60OlMzOSEQvF2= MXrTRW5ITVJ?
NCI-H1648 NH[3UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXKZ4NKSzVyPU[uOlc2PTdizszN M1vOZ3NCVkeHUh?=
LB771-HNC NHvPT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jGd2lEPTB;Nj65NlMxOSEQvF2= M2mxS3NCVkeHUh?=
SK-MEL-1 NEHTUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16w[2lEPTB;OD6xN|E3PiEQvF2= NVzGR2FMW0GQR1XS
COLO-668 M1PreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\lR2lEPTB;OD6yO|c5PiEQvF2= M3XreXNCVkeHUh?=
EW-12 NECx[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRThwNEC4NFMh|ryP MWHTRW5ITVJ?
A253 NYDQcmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TUOmlEPTB;OD64OFY3OSEQvF2= NUDBcZZ{W0GQR1XS
NCI-H2126 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHlV493UUN3ME24Mlg6OzF7IN88US=> M4W2S3NCVkeHUh?=
Calu-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRThwOUmwOFIh|ryP MoLBV2FPT0WU
NCI-H23 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrlWGxNUUN3ME25MlE4PzR4IN88US=> NWixNol2W0GQR1XS
WSU-NHL NX:zO4YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj4TWM2OD17Lke3OFc5KM7:TR?= MnrtV2FPT0WU
MMAC-SF MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkiyTWM2OD17Lkm3PVA1KM7:TR?= NXjTOVdLW0GQR1XS
SK-LMS-1 NF7RXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFyLkK4N|Qh|ryP MVrTRW5ITVJ?
GCIY NH3Yb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfNTII1UUN3ME2xNE42QTJ2IN88US=> NVnIPWtYW0GQR1XS
TE-15 MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzuTodQUUN3ME2xNU43ODB2IN88US=> MYTTRW5ITVJ?
EoL-1-cell MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[wR4hKSzVyPUGxMlc3QDJizszN MX\TRW5ITVJ?
NCI-H2081 M4D5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLke3PFYh|ryP NXjJeHF2W0GQR1XS
EW-3 M3TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rJSmlEPTB;MUKuNlQ3OyEQvF2= MVHTRW5ITVJ?
CAS-1 NGHVT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LRbmlEPTB;MUKuN|Y{OSEQvF2= NWC2dIx4W0GQR1XS
C2BBe1 NVv5UFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHZbW1KSzVyPUGyMlYyOzFizszN Mm\UV2FPT0WU
D-247MG NVfR[XhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF{Lke5OVIh|ryP NFHXVYRUSU6JRWK=
NCI-SNU-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK0ZlBKSzVyPUGyMlgxOTNizszN NFXHPHdUSU6JRWK=
LS-1034 NFLtVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrtTWM2OD1zND6zPVc2KM7:TR?= NV\zUFBLW0GQR1XS
EW-18 M{XUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofETWM2OD1zND60OFgh|ryP NEf1[GlUSU6JRWK=
Raji MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjXTWM2OD1zND61NFQ6KM7:TR?= NEjmSFNUSU6JRWK=
D-283MED MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHwTWM2OD1zND62NlcyKM7:TR?= MU\TRW5ITVJ?
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO5d3pKSzVyPUG0Mlk3QTZizszN M3XibnNCVkeHUh?=
NCI-SNU-16 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETnWIVKSzVyPUG1MlQ3OzNizszN NIHCVFVUSU6JRWK=
P30-OHK NEfHT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF5Lke4N|Eh|ryP MXLTRW5ITVJ?
RXF393 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF7LkCxPFYh|ryP Mkm4V2FPT0WU
NCI-H1395 NITH[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fzWmlEPTB;MkCuOlcxOyEQvF2= MXnTRW5ITVJ?
U-698-M MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;1TWM2OD1{MD63NFc2KM7:TR?= MXLTRW5ITVJ?
NCI-SNU-1 NEDjVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPQVVVXUUN3ME2yNE44OjJ|IN88US=> MmTpV2FPT0WU
SW684 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljkTWM2OD1{MT6xO|E3KM7:TR?= MYPTRW5ITVJ?
NCI-H716 NWDEbFY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H4UGlEPTB;MkGuN|E2PCEQvF2= NV3Ue2E3W0GQR1XS
JVM-2 NF7BdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXFTWM2OD1{MT60NVM{KM7:TR?= M3TjTXNCVkeHUh?=
NCI-H1581 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXHTWM2OD1{Mj60NVQ5KM7:TR?= NInpfIJUSU6JRWK=
CA46 NInRdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXPXIhKSzVyPUOxMlY6OzZizszN NUfPemhjW0GQR1XS
SNB75 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DOXmlEPTB;M{OuOlUxOyEQvF2= NUfTXVM1W0GQR1XS
KNS-42 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTN3Lkm2NlQh|ryP MmjtV2FPT0WU
TUR NES5bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;hcXZKSzVyPUO2MlA2OjFizszN MnnkV2FPT0WU
REH MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN5LkiyNVEh|ryP M4Pa[nNCVkeHUh?=
EW-22 M4fBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIewT5VKSzVyPUSyMlI5QDVizszN MmnXV2FPT0WU
NCI-H446 M2DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTR{Lke4OVMh|ryP MUfTRW5ITVJ?
ES3 NHi3O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKwWlg3UUN3ME20N{4yOzN7IN88US=> M12wPXNCVkeHUh?=
EW-11 M3zyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7PVHhKSzVyPUS0MlgzOThizszN NGPlXVlUSU6JRWK=
RH-1 NIf6T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFezdJRKSzVyPUS3MlU5OTJizszN MlvmV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275
Smiles NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat|Entinostat ic50|Entinostat price|Entinostat cost|Entinostat solubility dmso|Entinostat purchase|Entinostat manufacturer|Entinostat research buy|Entinostat order|Entinostat mouse|Entinostat chemical structure|Entinostat mw|Entinostat molecular weight|Entinostat datasheet|Entinostat supplier|Entinostat in vitro|Entinostat cell line|Entinostat concentration|Entinostat nmr|Entinostat in vivo|Entinostat clinical trial|Entinostat inhibitor|Entinostat Epigenetics inhibitor|Entinostat does|Entinostat mechanism of action|Entinostat sds
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID